| Name | Cyclin-dependent kinase 4 inhibitor D | ||
| UniProt ID | CDN2D_HUMAN | ||
| Gene Name | CDKN2D | ||
| Gene ID | 1032 | ||
| Synonyms |
CDKN2D, INK4D, p19, p19-INK4D
|
||
| Sequence |
MLLEEVRAGDRLSGAAARGDVQEVRRLLHRELVHPDALNRFGKTALQVMMFGSTAIALEL
LKQGASPNVQDTSGTSPVHDAARTGFLDTLKVLVEHGADVNVPDGTGALPIHLAVQEGHT AVVSFLAAESDLHRRDARGLTPLELALQRGAQDLVDILQGHMVAPL |
||
| Pathway Map | MAP LINK | ||
| KEGG ID | hsa1032 | ||
| Pfam | PF00023; PF12796; PF13606; PF13637; PF13857 | ||
| Pair Name | Sulforaphane, Everolimus | |||
| Phytochemical | Sulforaphane | |||
| Drug | Everolimus | |||
| Disease Info | [ICD-11: 2C94.Z] | Bladder cancer | Investigative | |
| Regulate Info | Up-regulation | Cyclin-dependent kinase 4 inhibitor D | Expression | |
| Result | The addition of SFN to the long-term everolimus application inhibits resistance development in bladder cancer cells in vitro. Therefore, sulforaphane may hold potential for treating bladder carcinoma in patients with resistance to an mTOR inhibitor. | |||
